Physician profile
Ling Yan Jiang
NPI 1578991964
$23,569.25
in general payments reported to CMS, 2019-2025
26 companies · $13K in 2025
The $13K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $534 · 2022: $1,502 · 2023: $2,201 · 2024: $5,886 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $11K · Food and Beverage: $9,152 · Consulting Fee: $1,180 · Education: $548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $10,653.64 |
| Food and Beverage | $9,152.28 |
| Consulting Fee | $1,180.00 |
| Education | $548.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $12,088.69 | 2024-2025 | |
| Janssen Biotech, INC. | $1,502.17 | 2022-2025 | Tremfya |
| Abbvie INC. | $1,493.67 | 2021-2025 | |
| Dermavant Sciences, INC. | $1,420.76 | 2023-2024 | Vtama |
| Leo Pharma INC. | $1,012.20 | 2023-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $910.80 | 2022-2025 | Ilumya |
| Genzyme Corporation | $816.62 | 2021-2025 | |
| Incyte Corporation | $646.43 | 2021-2025 | Opzelura, Opzelura |
| Galderma Laboratories, L.P. | $605.24 | 2024-2025 | Nemluvio, Aklief |
| Pfizer INC. | $549.97 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $525.95 | 2021-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $420.50 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $276.40 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $247.42 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Amgen INC. | $232.97 | 2021-2025 | Otezla, Otezla |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $196.39 | 2022-2025 | Sotyktu |
| Revance Therapeutics, INC. | $137.72 | 2025 | Daxxify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.08 | 2024 | Cyltezo |
| Ucb, INC. | $124.33 | 2025 | Bimzelx |
| Organon LLC | $45.05 | 2025 | Vtama |
| Aytu Biopharma, INC. | $42.61 | 2024 | Karbinal |
| Sanofi-Aventis U.S. LLC | $42.48 | 2021-2025 | |
| Botanix Sb INC | $35.13 | 2025 | Sofdra |
| Epi Health, LLC | $24.06 | 2021 | |
| Verrica Pharmaceuticals INC. | $21.67 | 2024 | Ycanth |
| Ibsa Pharma INC. | $19.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ling Yan Jiang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.